Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
03:47pm, Wednesday, 10'th Sep 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 2026
02:49pm, Wednesday, 10'th Sep 2025
Novo Nordisk A/S's job cuts and profit outlook reset reflect a strategic pivot to margin discipline, not long-term weakness, amid evolving GLP-1 market dynamics. Despite near-term margin pressure and
Novo Nordisk to cut 9,000 jobs
02:22pm, Wednesday, 10'th Sep 2025
CNBC's Michael Santoli and Melissa Lee discuss pharmaceutical company Novo Nordisk cutting jobs.
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such i
Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm
12:14pm, Wednesday, 10'th Sep 2025
Novo Nordisk A/S announced this morning that it will cut ~9k staff and that the one-off costs of doing so will severely impact profitability in 2025. Novo Nordisk's 2025 has been turbulent, but I beli
BENSALEM, Pa., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Novo Nordisk Cuts Around 9,000 Jobs as Weight-Loss Drugmaker Faces Growing Competition
11:55am, Wednesday, 10'th Sep 2025
Novo Nordisk (NVO) is making big job cuts as the weight-loss drugmaker faces growing competition.
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
11:30am, Wednesday, 10'th Sep 2025
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Ozempic Parent Announces 9,000 Job Cuts in Restructuring Plan
10:54am, Wednesday, 10'th Sep 2025
Pharmaceutical name Novo Nordisk A/S (NYSE:NVO), the maker of weight-loss drugs Wegovy and Ozempic, is in the spotlight today after announcing roughly 9,000 job cuts and slashing its full-year guidanc
Novo Nordisk: Priced Like Best Days Are Over [Upgrade]
10:00am, Wednesday, 10'th Sep 2025
Novo Nordisk is now deeply undervalued despite stellar fundamentals: 18% sales growth, 29% operating profit jump, and a rock-solid balance sheet. Growth is broad-based across obesity, diabetes, and ra
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs
09:24am, Wednesday, 10'th Sep 2025
The company downgraded its guidance for the second time in six weeks as it announced a restructuring plan.
Our H2 2025 Top Ideas
09:00am, Wednesday, 10'th Sep 2025
The US economy is showing signs of slowing, with the labor market cooling, consumer sentiment weak, Q3 GDP expected to slow to ~1.3%, and inflation still above the Fed's 2% target. Stagflation is now
Novo Nordisk Cuts 9,000 Jobs and Slashes Guidance. Why the Stock Is Rising.
06:32am, Wednesday, 10'th Sep 2025
The weight-loss drugs giant also slashed its profit guidance for the second time in six weeks.
Weight-loss drug manufacturer Novo Nordisk cuts 9000 jobs — and its profit forecast
04:47am, Wednesday, 10'th Sep 2025
New CEO Mike Doustdar is kitchen-sinking the costs of restructuring the company to focus on diabetes and anti-obesity drugs.
Novo Nordisk cuts 9K jobs to save $1.26B amid Wegovy growth, Eli Lilly rivalry
03:46am, Wednesday, 10'th Sep 2025
Novo Nordisk, the Danish pharmaceutical giant behind the obesity drug Wegovy, said on Wednesday it will cut about 9,000 jobs globally in a major restructuring effort, aiming to save 8 billion Danish c
